Dova Pharmaceuticals, Inc. (DOVA) Analysts See $-0.46 EPS

May 12, 2018 - By Kurt Siggers

Analysts expect Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) to report $-0.46 EPS on May, 17.After having $-0.36 EPS previously, Dova Pharmaceuticals, Inc.’s analysts see 27.78 % EPS growth. The stock increased 5.50% or $1.31 during the last trading session, reaching $25.23. About 267,694 shares traded or 52.42% up from the average. Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) has 0.00% since May 12, 2017 and is . It has underperformed by 11.55% the S&P500.

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. The company has market cap of $711.27 million. The Company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. It currently has negative earnings.

More important recent Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) news were published by: Nasdaq.com which released: “Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results” on May 09, 2018, also Seekingalpha.com published article titled: “Dova Pharmaceuticals’ (DOVA) CEO Alex Sapir on Q1 2018 Results – Earnings Call Transcript”, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For April 26, 2018” on April 26, 2018. More interesting news about Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) was released by: Benzinga.com and their article: “36 Biggest Movers From Yesterday” with publication date: May 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.